Shanghai Public Health Clinical Center and Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai, 201508, China.
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Virol Sin. 2021 Apr;36(2):167-175. doi: 10.1007/s12250-020-00294-3. Epub 2020 Sep 30.
Hand, foot, and mouth disease (HFMD) recently emerged as a global public threat. The licensure of inactivated enterovirus A71 (EV-A71) vaccine was the first step in using a vaccine to control HFMD. New challenges arise from changes in the pathogen spectrum while vaccines directed against other common serotypes are in the preclinical stage. The mission of a broad-spectrum prevention strategy clearly favors multivalent vaccines. The development of multivalent vaccines was attempted via the simple combination of potent monovalent vaccines or the construction of chimeric vaccines comprised of epitopes derived from different virus serotypes. The present review summarizes recent advances in HFMD vaccine development and discusses the next steps toward a safe and effective HFMD vaccine that is capable of establishing a cross-protective antibody response.
手足口病（HFMD）最近成为了一个全球性的公共威胁。肠道病毒 A71（EV-A71）灭活疫苗的上市是使用疫苗控制 HFMD 的第一步。当针对其他常见血清型的疫苗还处于临床前阶段时，病原体谱的变化带来了新的挑战。广谱预防策略的任务显然有利于多价疫苗。通过将有效的单价疫苗简单组合或构建由不同病毒血清型衍生的表位组成的嵌合疫苗，尝试了多价疫苗的开发。本综述总结了 HFMD 疫苗开发的最新进展，并讨论了朝着安全有效的 HFMD 疫苗迈进的下一步，该疫苗能够建立交叉保护抗体反应。
